Vol. 7, Issue 1, Part A (2025)

Endoxifen, a protein kinase C inhibitor (PKC), has been approved for use in bipolar affective disorder Recent literature depicts that it has been used in other disorders like impulsivity of borderline personality disorders, substance abuse and many more [2]. Here we upheld a series of cases showing multi-faceted use of the molecule in our daily clinical practice. There are documented evidences regarding efficacy of endoxifen in bipolar affective disorders and substantial data to suggest its benefit compared to the most commonly used mood stabilisers. But this molecule can give encouraging output in other major psychiatric illnesses if used effectively as depicted in our cases and its relatively safer side effect profile is an added cherry on the top of the cake. Further research and explorative studies are warranted to support the claim.